Invest in Neurocarrus

New first-in-class sensory neuron specific pain drug treats pain without risk of addiction

FIRST GOAL HIT (You can still invest)

$61,500

raised from 39 investors
INVESTMENT TERMS
Future Equity
$11.25M valuation cap

Highlights

1
Drug candidate N-001 provides relief from severe pain in animals caused by inflammation or surgery.
2
N-001 cannot enter the brain and therefore cannot cause addiction.
3
N-001 provides pain relief equal to prescription drugs without side effects on muscles or balance.
4
N-001 is a targeted drug with a unique manufacturing process to discourage competitors.

Featured Investor

Our Team


Publications:

Neurocarrus top scientific publications:

Animal efficacy and safety studies

Targeting, mechanism, and efficacy studies

Drug design and engineering studies

Future projections are not guaranteed








Overview